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Abstract
Background: Enzybiotics are becoming increasingly recognized as potential alternative therapies for drug-resistant
bacteria. Although only a few enzybiotics are currently well characterized, much information is still missing or is
unavailable for researchers. The construction of an enzybiotics database would therefore increase efficiency and
convenience in investigating these bioactive proteins and thus help reduce or delay the recent increase in
antibiotic resistance.
Description: In the present manuscript, we describe the development of a novel and original database called
EnzyBase, which contains 1144 enzybiotics from 216 natural sources. To ensure data quality, we limited the source
of information to authoritative public databases and published scientific literature. The interface of EnzyBase is easy
to use and allows users to rapidly retrieve data according to their desired search criteria and blast the database for
homologous sequences. We also describe examples of database-aided enzybiotics discovery and design.
Conclusion: EnzyBase serves as a unique tool for enzybiotic studies. It has several potential applications, e.g. in
silico enzybiotic combination as cocktails, and novel enzybiotic design, in response to continuously emerging drug-
resistant pathogens. This database is a valuable platform for researchers who are interested in enzybiotic studies.
EnzyBase is available online at http://biotechlab.fudan.edu.cn/database/EnzyBase/home.php.
Background
Antibiotic abuse is, in part, responsible for the dramatic
increase in the resistance of pathogens to traditional antibio-
tics [1]. Superbugs, such as MRSA and NDM-1, frequently
and seriously threaten public safety [2,3]. Consequently, the
need to develop new classes of antibiotics with novel
mechanisms of action against drug-resistant pathogens is
becoming very urgent. Enzybiotics [4-8] and antimicrobial
peptides (AMPs)[9] have attracted much attention as poten-
tial substitutes for conventional antibiotics.
In the present manuscript, enzybiotics are referred to as
bacterial cell wall-degrading enzymes, including lysins,
bacteriocins, autolysins, and lysozymes. The most impor-
tant characteristics of enzybiotics are their novel mechan-
isms of antibacterial action and capacity to kill antibiotic-
resistant bacteria [10]. Another significant feature of cer-
tain enzybiotics is their low probability of developing bac-
terial resistance [11]. Compared with AMPs, enzybiotics
are large, heat-labile, and narrow-spectrum types of anti-
microbial proteins. Consequently, enzybiotics are not
always suitable antimicrobial agents. Despite this, certain
enzybiotics have been well characterized and widely used.
Lysostaphin [12-15] and lysozymes [16-18] are the most
studied enzybiotics in regards to their clinical or food
applications. Furthermore, despite their apparent limita-
tions in medicine, their potency against multi-drug-resis-
tant pathogens should not be ignored. Therefore, an
enzybiotic specific database that not only mobilizes
research on enzybiotics, but also makes it more efficient
and convenient, needs to be constructed.
Over the past decade, many databases have been devel-
oped for AMPs. These databases, including APD [19,20],
ANTIMIC [21], CAMP [22], BACTIBASE [23,24], Phy-
tAMP [25], PenBase [26], Defensins [27], CyBase [28], and
peptaibols Peptaibol [29], contain AMP sequences from
diverse origins or specific families and accordingly have
accelerated and stimulated research on AMPs. Conversely,
the majority of the sequenced enzybiotics are stored in the
manually annotated UniProt/Swiss-Prot [30] database or
scattered in the scientific literature. As a result, it is diffi-
cult to find information on enzybiotics for recent users.
Developing a central database that stores information on
enzybiotics is warranted by investigators to promote their
research on enzybiotics discovery and design.
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any medium, provided the original work is properly cited.The idea of constructing a database that stores informa-
tion on enzybiotics arose from our own research experi-
ence. We found that we constantly had to query
information on enzybiotics from public databases, such as
UniProt, and scientific literature. Thus, we decided to con-
struct a database that simplified our research efforts, and
comprehensively collected this information. EnzyBase, a
novel and original database for enzybiotics studies, was
developed and currently contains 1144 enzybiotics from
216 natural sources. This database provides a platform for
current users to comprehensively and conveniently
research enzybiotics and can be useful for exploring and
designing novel enzybiotics for medical use.
Construction and content
EnzyBase was built on an Apache HTTP Server (V2.2.14)
with PHP (V5.2.13) and MySQL Server (V5.1.40) as the
back-end, and Personal Home Page (PHP), HyperText
Markup Language (HTML) and Cascading Style Sheets
(CSS) as the front-end. Apache, MySQL, and PHP were
preferred as they are open-source software and platform
independent, respectively, making them suitable for aca-
demic use. The web server and all parts of the database are
hosted at Information Office of Fudan University, Shang-
hai, China.
All enzybiotic sequences were collected manually from
the annotated UniProt/Swiss-Prot database or scientific
literature. Each enzybiotic without the UniProt link had
been excluded. The enzybiotics collected in EnzyBase
database are primarily from natural sources, with the
exception of genetically-modified sequences. Additional
physicochemical data of each enzybiotic was either calcu-
lated via Bioperl programs or identified from scientific
literature via a PubMed search. All of the collected infor-
mation was classified and filled into six relational tables
in MySQL. For each enzybiotic, a unique identification
number (i.e., enzy id) was assigned, beginning with the
prefix EN. Each entry also contains general data, such as
protein name, protein full name, producer organism, sim-
ple function annotation and protein sequence, domains,
3D structure, and relevant references. For all proteins
that already exist in the UniProt, Interpro [31], and/or
PDB [32] databases, hyperlinks to these databases were
created in EnzyBase. Additional physicochemical data,
including calculated isoelectric point (pI) and charge at
pI, are also provided. Moreover, minimal inhibitory con-
centrations (MICs) are included, if data are available. The
BlastP program (BLASTP V2.2.25+) [33,34] was used for
sequence homology searches against EnzyBase.
Utility and discussion
Database description
EnzyBase supplies a user-friendly web interface, so that
users can easily query and retrieve information on
enzybiotics. A concise navigational interface that con-
tains the database browse, search, tools, statistical infor-
mation, and guide, as well as a forum, were designed to
generate a clearly structured database layout that
enables fast and easy navigation (Figure 1).
As a web-based database, all data can be accessed and
retrieved directly from the web browser. The database
browse interface provides the users with a function of
navigating the entire database, whereas the search inter-
face provides the users with the function of retrieving
their desired information using either the “quick” or
“advanced” options. A “quick” search can be performed
using only keywords, while the “advanced” search offers
the possibility to specify seven separate fields, namely
enzy id, uniprotKB entry number (i.e., uniprot id), pro-
tein name, producer organism, domains, target organ-
ism, and MIC value. The user can query the database by
either one condition (excluding MIC, which requires the
type of target organism to be initially stated) or a com-
bination of various conditions. Every enzybiotic has its
own results page that contains comprehensive informa-
tion, including general information, antibacterial activ-
ities, sequence, structures, domains, and references. The
general information consists of enzy id, protein name,
protein full name, producer organism, protein mass, cal-
culated pI, antibacterial activity, and simple function
annotations. EnzyBase also provides hyperlinks to other
databases, such as UniProt, InterPro, PDB, and PubMed,
which allows for easier navigation within the World
Wide Web pertaining to additional information on
enzybiotics. The tools interface permits the use of
BLASTP against EnzyBase, which enables users to
search the database for homologous sequences, and
then copy obtained results for subsequent research.
Owing to limitations of disk space on the host site, we
did not implement a local BLASTP against the NCBI
database but instead supplied a hyperlink to the
BLASTP on the NCBI website. The statistical info inter-
face provides data on sources for enzybiotics, the distri-
bution of sequence length, protein mass, calculated
protein pI, and domains (please refer to the ‘Statistical
description and findings’ section below for more infor-
mation). The guide interface provides simple instruc-
tions for potential users on how to use the functions of
EnzyBase. Additionally, the forum tools, which are based
on UseBB, a free forum software, have been integrated
into the database to provide information on updates,
bug reports, and user discussions.
Statistical description and findings
The current version of EnzyBase possesses 1144 enzy-
biotics from 216 natural sources. The length of the
enzybiotic sequences range from 72 to 2337 amino
acids. Table 1 presents the top 10 sources for
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biotics have a calculated pI ranging from 4 to 11
(Figure 2).
All enzybiotics in EnzyBase contain 55 domains, and
only 24 enzybiotics have known 3D structures. The top
10 domains for the enzybiotics within EnzyBase are
Home Browse Database Search Tools Statistical Info Guide Forum    
Search EnzyBase
 
Enzy Id:     (Enzybase Id,such as EN10753092)
Uniprot Id:     (Uniprot Id,such as P10547)
Protein name:     (The name of Enzybiotic protein,such as lysostaphin)
Producer Organism:     (The source of enzybiotics,such as Streptococcus pneumoniae )
Domains:     (Pls. specify the name of domain,for example:Peptidase_M23)
Target Organism:     (Only enter one target organnism,for example:S. aureus )
MIC:   <   (ug/ml)(Please specify the target organism first!)
 
Search
Quick Search
Navigation  Bar
Home Browse Database Search Tools Statistical Info Guide Forum    
Current page (1/1)
1  Enzy_Id:EN10753092
    Name:LSTP_STASI
    Fullname:Lysostaphin
    Activity:Against  S. aureus,CNS
Lyses staphylococcal cells by hydrolyzing the polyglycine interpeptide bridges of the peptidoglycan.
2  Enzy_Id: EN57691756
    Name:LSTP_STAST
    Fullname:Lysostaphin
    Activity:Against  S. aureus,S. carnosus
Lyses staphylococcal cells by hydrolyzing the polyglycine interpeptide bridges of the peptidoglycan.
Result of Search
Record in detail
  Enzy_Id:
    Name:LSTP_STASI
    FullName:Lysostaphin
    Producer Organism:Staphylococcus simulans
    Sequence Length:493
    Mass:53091
    Isoelectric Point:5.27
    Target:S. aureus,CNS
    Link:P10547
    Function:Lyses staphylococcal cells by hydrolyzing the polyglycine interpeptide bridges of the peptidoglycan.
  Antibacterial Activities
  1  Flora:S. aureus  MIC:2.5ug/ml  Method:agar-dilu  [Pubmed:181936]
  2  Flora:S. capitis  MIC:60ug/ml  Method:agar-dilu  [Pubmed:181936]
  3  Flora:S. cohnii  MIC:8ug/ml  Method:agar-dilu  [Pubmed:181936]
  4  Flora:S. epidermidis  MIC:16ug/ml  Method:agar-dilu  [Pubmed:181936]
Record of Entry
Figure 1 Screen shots of the EnzyBase search interface. Screen shots of the EnzyBase search interface showing the advanced search and
result views. Please note that not all fields are shown.
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domain (till 2012-2-6). In fact, this domain is carried by
392 enzybiotics, representing ca. 34% of the total num-
ber of enzybiotics in EnzyBase. Thus, it appears that
many of the recorded enzybiotics are amidase like.
Applications
The EnzyBase can be used as a tool to aid researchers in
exploring the use of enzybiotics or for designing novel
enzybiotics. The most prominent weakness of enzybiotics
is their narrow spectrum of antibacterial activity. However,
a combination of enzybiotics with different spectra of anti-
bacterial activities and/or different mechanisms of action
could be used against a broad spectrum of bacterial infec-
tions and/or their resistant strains. Through the use of
EnzyBase, users can quickly find a series of enzybiotics
with optimum antibacterial activities against specific
pathogens, and then combine them as a cocktail to mea-
sure their therapeutic effect against bacterial infectious
diseases. Similar approaches have been successfully used
to design phage cocktail therapies for the treatment of
infections [35]. For novel enzybiotics design, users could
search for potential domains with high antibacterial activ-
ities against specific pathogens on EnzyBase and then
combine them to create chimeric enzybiotics. For instance,
to search for effective antimicrobial proteins against masti-
tis-causing pathogens, researchers created a novel chi-
meric peptidoglycan hydrolase fusion protein between
lysostaphin and the endolysin of phage B30, which pos-
sesses their respective enzymatic domains, and is capable
of degrading both streptococcal and staphylococcal pepti-
doglycans [36]. Thus, the quantity and quality of the data
entered in EnzyBase appears to be very important for suc-
cessfully applying it in such research applications.
In the future, we plan to implement updates, assess the
data quality continuously, and integrate some structural
analysis tools, such as RasMol [37], and certain web2.0
functions, such as Wiki, into EnzyBase to improve its
interactivity with users and improve research in the field
of enzybiotics design and structure function exploration.
Conclusions
In summary, EnzyBase is a comprehensive and web-
accessible database of enzybiotics. The current version of
EnzyBase has 1144 entries. The database can be queried
either by using simply keywords or by combinatorial con-
ditions searches. EnzyBase may aid in enhancing our cur-
rent understanding of enzybiotics and their mechanisms
of action. Its potential applications include the in silico
development of combinations of enzybiotics (e.g., cock-
tails) and the construction of novel enzybiotics against
various bacterial infectious diseases. Thus, the database
may have implications in the development of new drugs
for medical applications.
Availability and requirements
EnzyBase is freely available for academic users at http://
biotechlab.fudan.edu.cn/database/EnzyBase/home.php.
Table 1 Top 10 sources of enzybiotics in EnzyBase
Rank Producer organisms Numbers of enzybiotics
1 Staphylococcus aureus 142
2 Enterococcus faecalis 136
3 Bacillus cereus 73
4 Streptococcus pneumoniae 66
5 Bacillus thuringiensis 57
6 Staphylococcus phage 55
7 Listeria monocytogenes 28
8 Staphylococcus epidermidis 27
9 Clostridium perfringens 21
10 Enterococcus faecium 21
Figure 2 Distribution of calculated isoelectric points for the
enzybiotics within EnzyBase. Every bar indicates the number of
enzybiotics calculated to have their isoelectric point range from pI 1
to 14.
Table 2 Top 10 domains in EnzyBase
Rank Interpro
Id
Domain Name Numbers of
enzybiotics
1 IPR002502 Amidase_domain 392
2 IPR007921 CHAP 224
3 IPR017853 Glycoside_hydrolase_SF 188
4 IPR002053 Glyco_hydro_25 188
5 IPR013781 Glyco_hydro_subgr_catalytic 187
6 IPR002901 Mano_Glyc_endo_b_GlcNAc 169
7 IPR018392 Peptidoglycan-bd_lysin 147
8 IPR013667 SH3_5_bac 141
9 IPR002482 Peptidoglycan-
bd_Lysin_subgr
141
10 IPR003646 SH3-like_bac 134
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